分化型甲状腺癌(DTC)因其发病率逐年增高而引人关注,伴随着核医学诊疗一体化手段的不断完善以及分子生物学等技术在DTC中的深入研究,有关其诊断及治疗理念也在不断更新.本文结合现有的诊疗一体化实践以及循证医学证据和相关指南推荐,对131I治疗前评估体系进行系统阐述.
With the increase of its incidence,differentiated thyroid carcinoma(DTC)has become a global concern.Over the recent decades,the guidelines for the management of DTC have been kept updating along with the development of nuclear medicine theranostics and molecular biology.The present article will systematically expound on the 131I pre-treatment evaluation system based on the clinical practice of nuclear medicine theranostics,the latest evidence-based medical evidence,and guideline recommendations.